DRI Capital is marketing another $150 million of bonds backed by royalties flowing from pharmaceutical patents on established drugs, according to Kroll Bond Rating Agency.

The series 2017-1 notes will be issued from the same master trust as the series 2016-1 trust, which have an outstanding balance of approximately $116 million.

Subscribe Now

Access to a full range of industry content, analysis and expert commentary.

30-Day Free Trial

No credit card required. Access coverage of the securitization marketplace, including breaking news updated throughout the day.